Erisyon Inc. is at the forefront of proteomics with its groundbreaking single molecule protein sequencing technology, known as Fluorosequencing. This innovative technology allows for the cataloging and quantification of every peptide and protein molecule in a biological sample, enabling a wide range of applications in biology and medicine. The company's core product is the first commercial single molecule protein sequencer, which has the potential to revolutionize the detection, treatment, and monitoring of diseases. Erisyon's technology is particularly valuable in areas such as cancer vaccine therapies, single cell proteomics, and the early detection of biomarkers in neurodegenerative diseases. Founded in March 2018 by a team of technologists and entrepreneurs from the University of Texas at Austin's Center for Systems and Synthetic Biology, Erisyon aims to drive new discoveries that improve global health and safety. The company serves clients in the pharmaceutical, agricultural, and clinical research sectors, operating in the rapidly growing proteomics market. Erisyon's business model involves selling its sequencing technology and providing related services, generating revenue through product sales, service contracts, and collaborations with research institutions and biotech companies.

Keywords: proteomics, single molecule sequencing, Fluorosequencing, cancer vaccines, biomarkers, neurodegenerative diseases, post-translational modifications, drug development, agricultural biotechnology, clinical research.